Cargando…
Rates of virological failure in patients treated in a home-based versus a facility-based HIV-care model in Jinja, southeast Uganda: a cluster-randomised equivalence trial
BACKGROUND: Identification of new ways to increase access to antiretroviral therapy in Africa is an urgent priority. We assessed whether home-based HIV care was as effective as was facility-based care. METHODS: We undertook a cluster-randomised equivalence trial in Jinja, Uganda. 44 geographical are...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Lancet Publishing Group
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2806484/ https://www.ncbi.nlm.nih.gov/pubmed/19939445 http://dx.doi.org/10.1016/S0140-6736(09)61674-3 |
_version_ | 1782176311408590848 |
---|---|
author | Jaffar, Shabbar Amuron, Barbara Foster, Susan Birungi, Josephine Levin, Jonathan Namara, Geoffrey Nabiryo, Christine Ndembi, Nicaise Kyomuhangi, Rosette Opio, Alex Bunnell, Rebecca Tappero, Jordan W Mermin, Jonathan Coutinho, Alex Grosskurth, Heiner |
author_facet | Jaffar, Shabbar Amuron, Barbara Foster, Susan Birungi, Josephine Levin, Jonathan Namara, Geoffrey Nabiryo, Christine Ndembi, Nicaise Kyomuhangi, Rosette Opio, Alex Bunnell, Rebecca Tappero, Jordan W Mermin, Jonathan Coutinho, Alex Grosskurth, Heiner |
author_sort | Jaffar, Shabbar |
collection | PubMed |
description | BACKGROUND: Identification of new ways to increase access to antiretroviral therapy in Africa is an urgent priority. We assessed whether home-based HIV care was as effective as was facility-based care. METHODS: We undertook a cluster-randomised equivalence trial in Jinja, Uganda. 44 geographical areas in nine strata, defined according to ratio of urban and rural participants and distance from the clinic, were randomised to home-based or facility-based care by drawing sealed cards from a box. The trial was integrated into normal service delivery. All patients with WHO stage IV or late stage III disease or CD4-cell counts fewer than 200 cells per μL who started antiretroviral therapy between Feb 15, 2005, and Dec 19, 2006, were eligible, apart from those living on islands. Follow-up continued until Jan 31, 2009. The primary endpoint was virological failure, defined as RNA more than 500 copies per mL after 6 months of treatment. The margin of equivalence was 9% (equivalence limits 0·69–1·45). Analyses were by intention to treat and adjusted for baseline CD4-cell count and study stratum. This trial is registered at http://isrctn.org, number ISRCTN 17184129. FINDINGS: 859 patients (22 clusters) were randomly assigned to home and 594 (22 clusters) to facility care. During the first year, 93 (11%) receiving home care and 66 (11%) receiving facility care died, 29 (3%) receiving home and 36 (6%) receiving facility care withdrew, and 8 (1%) receiving home and 9 (2%) receiving facility care were lost to follow-up. 117 of 729 (16%) in home care had virological failure versus 80 of 483 (17%) in facility care: rates per 100 person-years were 8·19 (95% CI 6·84–9·82) for home and 8·67 (6·96–10·79) for facility care (rate ratio [RR] 1·04, 0·78–1·40; equivalence shown). Two patients from each group were immediately lost to follow-up. Mortality rates were similar between groups (0·95 [0·71–1·28]). 97 of 857 (11%) patients in home and 75 of 592 (13%) in facility care were admitted at least once (0·91, 0·64–1·28). INTERPRETATION: This home-based HIV-care strategy is as effective as is a clinic-based strategy, and therefore could enable improved and equitable access to HIV treatment, especially in areas with poor infrastructure and access to clinic care. FUNDING: US Centers for Disease Control and Prevention and UK Medical Research Council. |
format | Text |
id | pubmed-2806484 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2009 |
publisher | Lancet Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-28064842010-01-29 Rates of virological failure in patients treated in a home-based versus a facility-based HIV-care model in Jinja, southeast Uganda: a cluster-randomised equivalence trial Jaffar, Shabbar Amuron, Barbara Foster, Susan Birungi, Josephine Levin, Jonathan Namara, Geoffrey Nabiryo, Christine Ndembi, Nicaise Kyomuhangi, Rosette Opio, Alex Bunnell, Rebecca Tappero, Jordan W Mermin, Jonathan Coutinho, Alex Grosskurth, Heiner Lancet Articles BACKGROUND: Identification of new ways to increase access to antiretroviral therapy in Africa is an urgent priority. We assessed whether home-based HIV care was as effective as was facility-based care. METHODS: We undertook a cluster-randomised equivalence trial in Jinja, Uganda. 44 geographical areas in nine strata, defined according to ratio of urban and rural participants and distance from the clinic, were randomised to home-based or facility-based care by drawing sealed cards from a box. The trial was integrated into normal service delivery. All patients with WHO stage IV or late stage III disease or CD4-cell counts fewer than 200 cells per μL who started antiretroviral therapy between Feb 15, 2005, and Dec 19, 2006, were eligible, apart from those living on islands. Follow-up continued until Jan 31, 2009. The primary endpoint was virological failure, defined as RNA more than 500 copies per mL after 6 months of treatment. The margin of equivalence was 9% (equivalence limits 0·69–1·45). Analyses were by intention to treat and adjusted for baseline CD4-cell count and study stratum. This trial is registered at http://isrctn.org, number ISRCTN 17184129. FINDINGS: 859 patients (22 clusters) were randomly assigned to home and 594 (22 clusters) to facility care. During the first year, 93 (11%) receiving home care and 66 (11%) receiving facility care died, 29 (3%) receiving home and 36 (6%) receiving facility care withdrew, and 8 (1%) receiving home and 9 (2%) receiving facility care were lost to follow-up. 117 of 729 (16%) in home care had virological failure versus 80 of 483 (17%) in facility care: rates per 100 person-years were 8·19 (95% CI 6·84–9·82) for home and 8·67 (6·96–10·79) for facility care (rate ratio [RR] 1·04, 0·78–1·40; equivalence shown). Two patients from each group were immediately lost to follow-up. Mortality rates were similar between groups (0·95 [0·71–1·28]). 97 of 857 (11%) patients in home and 75 of 592 (13%) in facility care were admitted at least once (0·91, 0·64–1·28). INTERPRETATION: This home-based HIV-care strategy is as effective as is a clinic-based strategy, and therefore could enable improved and equitable access to HIV treatment, especially in areas with poor infrastructure and access to clinic care. FUNDING: US Centers for Disease Control and Prevention and UK Medical Research Council. Lancet Publishing Group 2009-12-19 /pmc/articles/PMC2806484/ /pubmed/19939445 http://dx.doi.org/10.1016/S0140-6736(09)61674-3 Text en © 2009 Elsevier Ltd. All rights reserved. This document may be redistributed and reused, subject to certain conditions (http://www.elsevier.com/wps/find/authorsview.authors/supplementalterms1.0) . |
spellingShingle | Articles Jaffar, Shabbar Amuron, Barbara Foster, Susan Birungi, Josephine Levin, Jonathan Namara, Geoffrey Nabiryo, Christine Ndembi, Nicaise Kyomuhangi, Rosette Opio, Alex Bunnell, Rebecca Tappero, Jordan W Mermin, Jonathan Coutinho, Alex Grosskurth, Heiner Rates of virological failure in patients treated in a home-based versus a facility-based HIV-care model in Jinja, southeast Uganda: a cluster-randomised equivalence trial |
title | Rates of virological failure in patients treated in a home-based versus a facility-based HIV-care model in Jinja, southeast Uganda: a cluster-randomised equivalence trial |
title_full | Rates of virological failure in patients treated in a home-based versus a facility-based HIV-care model in Jinja, southeast Uganda: a cluster-randomised equivalence trial |
title_fullStr | Rates of virological failure in patients treated in a home-based versus a facility-based HIV-care model in Jinja, southeast Uganda: a cluster-randomised equivalence trial |
title_full_unstemmed | Rates of virological failure in patients treated in a home-based versus a facility-based HIV-care model in Jinja, southeast Uganda: a cluster-randomised equivalence trial |
title_short | Rates of virological failure in patients treated in a home-based versus a facility-based HIV-care model in Jinja, southeast Uganda: a cluster-randomised equivalence trial |
title_sort | rates of virological failure in patients treated in a home-based versus a facility-based hiv-care model in jinja, southeast uganda: a cluster-randomised equivalence trial |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2806484/ https://www.ncbi.nlm.nih.gov/pubmed/19939445 http://dx.doi.org/10.1016/S0140-6736(09)61674-3 |
work_keys_str_mv | AT jaffarshabbar ratesofvirologicalfailureinpatientstreatedinahomebasedversusafacilitybasedhivcaremodelinjinjasoutheastugandaaclusterrandomisedequivalencetrial AT amuronbarbara ratesofvirologicalfailureinpatientstreatedinahomebasedversusafacilitybasedhivcaremodelinjinjasoutheastugandaaclusterrandomisedequivalencetrial AT fostersusan ratesofvirologicalfailureinpatientstreatedinahomebasedversusafacilitybasedhivcaremodelinjinjasoutheastugandaaclusterrandomisedequivalencetrial AT birungijosephine ratesofvirologicalfailureinpatientstreatedinahomebasedversusafacilitybasedhivcaremodelinjinjasoutheastugandaaclusterrandomisedequivalencetrial AT levinjonathan ratesofvirologicalfailureinpatientstreatedinahomebasedversusafacilitybasedhivcaremodelinjinjasoutheastugandaaclusterrandomisedequivalencetrial AT namarageoffrey ratesofvirologicalfailureinpatientstreatedinahomebasedversusafacilitybasedhivcaremodelinjinjasoutheastugandaaclusterrandomisedequivalencetrial AT nabiryochristine ratesofvirologicalfailureinpatientstreatedinahomebasedversusafacilitybasedhivcaremodelinjinjasoutheastugandaaclusterrandomisedequivalencetrial AT ndembinicaise ratesofvirologicalfailureinpatientstreatedinahomebasedversusafacilitybasedhivcaremodelinjinjasoutheastugandaaclusterrandomisedequivalencetrial AT kyomuhangirosette ratesofvirologicalfailureinpatientstreatedinahomebasedversusafacilitybasedhivcaremodelinjinjasoutheastugandaaclusterrandomisedequivalencetrial AT opioalex ratesofvirologicalfailureinpatientstreatedinahomebasedversusafacilitybasedhivcaremodelinjinjasoutheastugandaaclusterrandomisedequivalencetrial AT bunnellrebecca ratesofvirologicalfailureinpatientstreatedinahomebasedversusafacilitybasedhivcaremodelinjinjasoutheastugandaaclusterrandomisedequivalencetrial AT tapperojordanw ratesofvirologicalfailureinpatientstreatedinahomebasedversusafacilitybasedhivcaremodelinjinjasoutheastugandaaclusterrandomisedequivalencetrial AT merminjonathan ratesofvirologicalfailureinpatientstreatedinahomebasedversusafacilitybasedhivcaremodelinjinjasoutheastugandaaclusterrandomisedequivalencetrial AT coutinhoalex ratesofvirologicalfailureinpatientstreatedinahomebasedversusafacilitybasedhivcaremodelinjinjasoutheastugandaaclusterrandomisedequivalencetrial AT grosskurthheiner ratesofvirologicalfailureinpatientstreatedinahomebasedversusafacilitybasedhivcaremodelinjinjasoutheastugandaaclusterrandomisedequivalencetrial AT ratesofvirologicalfailureinpatientstreatedinahomebasedversusafacilitybasedhivcaremodelinjinjasoutheastugandaaclusterrandomisedequivalencetrial |